Volume : 13, Issue : 04, April – 2026
Title:
DESIGN AND DEVELOPMENT OF VORICONAZOLE LOADED SOLID LIPID NANOPARTICLES BY QUALITY-BY-DESIGN
Authors :
Y. Sarah Sujitha *, Peddisetty Yoshitha
Abstract :
The purpose of this study was to design and development of Voriconazole loaded solid lipid nanoparticles by quality-by-design. Voriconazole loaded solid lipid nanoparticles, was prepared by High pressure homogenization technique, Cold homogenization technique and Solvent emulsification-evaporation technique. Results: Fourier Transform Infra-Red (FTIR) Spectroscopy and differential scanning colorimetry (DSC) reveals there is interaction between drug and formulation excipients. % Entrapment efficiency was found to be 87.5 +2.19. Zeta potential value of more than ±30 is considered the reference value to derive a physical stable dispersion system. The mean particle size of optimized formulation of SLNs showed particle size below 200 nm. Transmission electron microscopy (TEM) particles showed spherical and uniform shape
Key words: Solid lipid nanoparticles, High pressure homogenization technique, Cold homogenization technique and Solvent emulsification-evaporation technique.
Cite This Article:
Please cite this article in press Y. Sarah Sujitha et al., Design And Development Of Voriconazole Loaded Solid Lipid Nanoparticles By Quality-By-Design., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Ku, M.S., Dulin, W., 2010. A biopharmaceutical classification-based Right- First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of- Concept. Pharmaceutical Development & Technology, 1–18.
2. Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L.X., Amidon, G.L., 2006. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Molecular Pharmaceutics3, 631–643.
3. Horter, D., Dressman, J.B., 2001. Influence of physicochemical properties on dissolutionof drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews 46,75–87.
4. Stella, V.J., Nti-Addae, K.W., 2007. Prodrug strategies to overcome poor water solubility.Advance Drug Delivery Review 59, 677–694.
5. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research 12, 413–420.
6. Wu, C.Y., Benet, L.Z., 2005. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 22, 11–23.
7. Lobenberg, R., Amidon, G.L., 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics50, 3–12.
8. Horter, D., Dressman, J.B., 2001. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews 46,75–87.
9. Blagden, N., de Matas, M., Gavan, P.T., York, P., 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Advanced Drug Delivery Reviews 59, 617–630.
10. R. Janknecht, S.De Marie, I.A.J.M. Bakker-Woudenberg, D.J.A.Crommelin, Liposomal and lipid formulations of amphotericin B,Clin. Pharmacokinet. 23(1992)279–291.
11. P. Couvreur, C. Dubernet, F. Puisieux, Controlled drug delivery with nanoparticles: current possibilities and future trends, Eur. J. Pharm. Biopharm. 41 (1995)2–13.
12. R.H. Mu¨ller, K. Peters, Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique, Int .J. Pharm. 160 (1998) 229–237.
13. R. J. Prankerd, V.J.Stella, The use of oil-in-water emulsions as a vehicle for parenteral drug administration, J. Parent .Sci. Technol.44 (1990)139–149.
14. T. Eldem, P. Speiser, A. Hincal, Optimization of spray-dried and congealed lipid micropellet sand characterization of their surface morphology by scanning electron microscopy, Pharm. Res.8 (1991)47–54.
15. P. Speiser, Lipid nanopellet sals Tra¨gersystemfu¨r Arzne imittelzurperoralen An wendung, European Patent EP0167825, 1990.
16. R.H. Mu¨ller, J.S.Lucks, Arzneistofftra¨gerausfesten Lipid- teilchen, Feste Lipid nanospha¨ren (SLN), European Patent No.0605497, 1996.
17. R. Cavalli, O. Caputo, M.R. Gasco, Solid lipospheres of doxorubicin and idarubicin, Int .J. Pharm.89 (1993) R9- R12.
18. R.H.Mu¨ller, S. A. Runge, Solid lipid nanoparticles (SLN) for controlled drug delivery, in: S. Benita (Ed.), Submicron Emulsions in Drug Targeting and Delivery, Harwood AcademicPublishers,Amsterdam,1998,pp.219–234.
19. R .H. Mu¨ller, W. Mehnert, J. S. Lucks, C.Schwarz, A.zur Mu¨hlen, H. Weyhers, C. Freitas, D. Ru¨hl, solid lipid nanoparticles (SLN) : An alternative colloidal carrier system for controlled drug delivery, Eur. J. Pharm. Bio- pharm.41(1995)62–69.